Literature DB >> 19509252

Lysophosphatidic acid stimulates cell migration, invasion, and colony formation as well as tumorigenesis/metastasis of mouse ovarian cancer in immunocompetent mice.

Hui Li1, Dongmei Wang, Hong Zhang, Kashif Kirmani, Zhenwen Zhao, Rosemary Steinmetz, Yan Xu.   

Abstract

We have already established human xenographic models for the effect of lysophosphatidic acid (LPA) on tumor metastasis in vivo. The purpose of this work is to establish a preclinical LPA effect model in immunocompetent mice. We first characterized the mouse epithelial ovarian cancer (EOC) cell line ID8 for its responsiveness to LPA in cell proliferation, migration, and invasion and compared these properties with those of human EOC. The signaling pathways related to cell migration were further investigated using pharmacologic and genetic approaches. The effects of LPA on the tumorigenesis of ID8 cells and mouse survival were then examined using two different mouse models (i.p. and orthotopic injections). LPA stimulated cell proliferation, migration, and invasion of mouse EOC ID8 cells in a manner closely resembling its activity in human EOC cells. The signaling pathways involved in LPA-induced cell migration in ID8 cells were also similar to those identified in human EOC cells. We have identified cyclooxygenase-1 and 15-lipoxygenase as two new signaling molecules involved in LPA-induced cell migration in both human and mouse EOC cells. In addition, LPA enhanced the tumorigenesis/metastasis of ID8 cell in vivo as assessed by increased tumor size, early onset of ascites formation, and reduced animal survival. We have established the first LPA-EOC preclinical model in immunocompetent mice. Because ID8 cells respond to LPA similar to human EOC cells, this model is very valuable in developing and testing therapeutic reagents targeting LPA in EOC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19509252     DOI: 10.1158/1535-7163.MCT-08-1106

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  29 in total

1.  Group VIA phospholipase A2 in both host and tumor cells is involved in ovarian cancer development.

Authors:  Hui Li; Zhenwen Zhao; Gang Wei; Libo Yan; Dongmei Wang; Hong Zhang; George Earl Sandusky; John Turk; Yan Xu
Journal:  FASEB J       Date:  2010-06-08       Impact factor: 5.191

2.  Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer.

Authors:  Feng Su; Kathy R Kozak; Satoshi Imaizumi; Feng Gao; Malaika W Amneus; Victor Grijalva; Carey Ng; Alan Wagner; Greg Hough; Gina Farias-Eisner; G M Anantharamaiah; Brian J Van Lenten; Mohamad Navab; Alan M Fogelman; Srinivasa T Reddy; Robin Farias-Eisner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

3.  Cytosolic phospholipase A2 as a molecular target for the radiosensitization of ovarian cancer.

Authors:  Rachael R Schulte; Amanda G Linkous; Dennis E Hallahan; Eugenia M Yazlovitskaya
Journal:  Cancer Lett       Date:  2011-05-28       Impact factor: 8.679

Review 4.  Lipid phosphate phosphatases and their roles in mammalian physiology and pathology.

Authors:  Xiaoyun Tang; Matthew G K Benesch; David N Brindley
Journal:  J Lipid Res       Date:  2015-03-26       Impact factor: 5.922

Review 5.  GPCRs and cancer.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Acta Pharmacol Sin       Date:  2012-01-23       Impact factor: 6.150

6.  LPA1 receptor-mediated thromboxane A2 release is responsible for lysophosphatidic acid-induced vascular smooth muscle contraction.

Authors:  Péter Tibor Dancs; Éva Ruisanchez; Andrea Balogh; Cecília Rita Panta; Zsuzsanna Miklós; Rolf M Nüsing; Junken Aoki; Jerold Chun; Stefan Offermanns; Gábor Tigyi; Zoltán Benyó
Journal:  FASEB J       Date:  2017-01-09       Impact factor: 5.191

7.  Combination therapy of an inhibitor of group VIA phospholipase A2 with paclitaxel is highly effective in blocking ovarian cancer development.

Authors:  Hui Li; Zhenwen Zhao; Caryl Antalis; Zhanzhong Zhao; Robert Emerson; Gang Wei; Sheng Zhang; Zhong-Yin Zhang; Yan Xu
Journal:  Am J Pathol       Date:  2011-05-17       Impact factor: 4.307

8.  Integrity of SOS1/EPS8/ABI1 tri-complex determines ovarian cancer metastasis.

Authors:  Huijun Chen; Xufeng Wu; Zhixing K Pan; Shuang Huang
Journal:  Cancer Res       Date:  2010-11-30       Impact factor: 12.701

9.  Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells.

Authors:  Q Cai; L Yan; Y Xu
Journal:  Oncogene       Date:  2014-08-18       Impact factor: 9.867

10.  Effects of lysophospholipids on tumor microenvironment.

Authors:  Johannes Rolin; Azzam A Maghazachi
Journal:  Cancer Microenviron       Date:  2011-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.